South Korea's CJ launches world's first antibiotic replacement

Cheiljedang Corporation has developed a new kind of antibiotic-replacement for use in poultry feed amid the growing global market for safe antibiotic alternatives.

 

According to the company, its latest product, Biotector, is the world's first bacteriophage product used as a feed additive to fight harmful bacteria like salmonella gallinarum and salmonella pullorum, which cause typhoid and other diseases in fowl.

 

"We have developed the world's first antibiotic replacement that is safe for both fowl and human consumption," chief executive Kim Jin-soo said.

 

The CEO said the new product is the result of research conducted since 2006 on an investment of KRW5 billion (US$4.4 million). The company has set KRW1.3 billion (US$1.1 million) as its sales target for 2010 and KRW240 billion (US$211.9 million) for 2015.

 

Various countries have adopted regulations to ban the use of antibiotics for livestock believed to be harmful to human health. While the ban has taken place much earlier in advanced economies, like the EU in 2006, such ban in Korea is scheduled to take effect in 2012.

 

Kim said CJ's antibiotic replacement is cost-competitive, assuring that Korean farmers will not feel a sudden cost burden. This would mean that local consumers also do not have to worry about a surge in the prices of poultry products.

 

Kim Jin-dong, the team leader of CJ's Animal Nutrition and Health department, noted that the current alternatives to antibiotics have been the acidifier, probiotics, enzymes, and prebiotics.

 

"The controversy surrounding antibiotics is that they weaken the resistance of animals to various diseases, while raising questions over their safety for human consumption," the animal nutritionist said.

 

CJ's Biotector has made its debut in the home market and India. Next year, the company plans to expand to Brazil and China.

 

Capturing the global market is expected to take time due to the examination and approval period required by each of CJ's targeted countries. "We expect to enter the EU region in 2016, because it is expected to take up to seven years to go through the approval process," Kim Jin-dong said.

 

The entry and approval process is also estimated to cost about EUR7 million (US$9.5 million), he added.